ClinicalTrials.gg
CompletedNCT02939014Updated Feb 24, 2021Results posted

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

A Phase 2 interventional study of Brentuximab Vedotin in Hodgkin Disease and Lymphoma, Large-Cell, Anaplastic, sponsored by Takeda. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
53rd of 80
39 · median 52
Started
2016
with 5 others
Phase 2
41 of 80
8 open now
Registered
49th of 80
by date
Lead sponsor
4 of 80
Takeda

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 53rd largest by enrollment, is one of 6 that started in 2016, is one of 41 in phase 2, and was the 49th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL).

Read the detailed description

The drug being tested in this study is called brentuximab vedotin. This study will look at efficacy, safety and PK of brentuximab vedotin in Chinese participants with relapsed/refractory CD30+ HL or sALCL.

The study will enroll approximately 30 patients. Participants will receive:

  • Brentuximab vedotin 1.8 mg/kg

All participants will be administered IV infusion on Day 1 each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.

This multi-center trial will be conducted in China only. The overall time to participate in this study is 3.5 years. Participants will make multiple visits to the clinic, and will be followed for overall survival (OS) every 12 weeks until death, withdrawal of consent, 18 months after end of treatment (EOT) or study closure, whichever occurs first.

03

Conditions studied

  • Hodgkin Disease
  • Lymphoma, Large-Cell, Anaplastic

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have confirmed CD30+ hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Immunohistochemistry or flow cytometry may be performed on either original diagnostic material or biopsy of disease, and pathology reports of CD30+ or their copies should be retained at the site.
  2. With CD30+ HL or sALCL who have relapsed from or are refractory to previous treatments.
  3. Fluorodeoxyglucose (FDG)- positron emission tomography (PET) positive and of at least 1.5 cm in the longest diameter by computed tomography (CT), as assessed by the site.
  4. Must have an (ECOG) performance status of 0 or 1.
  5. Suitable venous access for the study-required blood sampling, including pharmacokinetic (PK) sampling.
  6. Must have the following required screening laboratory data. Participants must not have received recombinant granulocyte-colony stimulating factor (G-CSF) or transfusion within 1 week before the screening hematology assessment.

    1. ≥1500/μL.
    2. Platelet count ≥75,000/μL.
    3. Serum level ≤1.5 times the (ULN).
    4. Serum creatinine level ≤1.5 times the ULN.
    5. (ALT) and aspartate aminotransferase (AST) ≤2.5 times the ULN.
  7. Survival for 3 or more months must be expected.

Exclusion criteria

Exclusion Criteria:

  1. With current diagnosis of primary cutaneous anaplastic large cell lymphoma (ALCL) (participants with other organ involvement who have transformed to sALCL are eligible).
  2. With any active viral, bacterial, or fungal infection within 2 weeks before the first dose of brentuximab vedotin.
  3. With cardiac failure categorized as Class III or IV according to the criteria, uncontrolled coronary artery disease or uncontrolled arrhythmia despite of appropriate medical therapy, or a history of myocardial infarction within 6 months before the first dose of brentuximab vedotin.
  4. With uncontrolled diabetes mellitus.
  5. Peripheral neuropathy ≥Grade 2.
  6. With a history of another that has not been in remission for at least 3 years. The following are exempt from the 3-year limit:

    1. Nonmelanoma skin cancer.
    2. Curatively treated localized prostate cancer.
    3. Cervical carcinoma in situ.
  7. With known cerebral/meningeal disease (HL or any other etiology), including signs or symptoms of progressive multifocal leukoencephalopathy (PML).
  8. With a positive result in the screening test for (HIV) antibody.
  9. Known virus (HBV) surface antigen seropositive or positive virus (HCV) antibody. Note: participants who have positive HBV core antibody can be enrolled but must have an undetectable HBV viral load.
  10. With a history of liver fibrosis or cirrhosis and clinical signs and symptoms indicating liver fibrosis or cirrhosis.
  11. Have received stem cell transplantation (auto-SCT) within 12 weeks before the first dose of brentuximab vedotin.
  12. With history of allogeneic stem cell transplantation (allo-SCT).
  13. Have received treatment for malignancies (including radiation, chemotherapy, and hormone therapy) within 4 weeks before the first dose of brentuximab vedotin and participants who have received treatment for malignancies with biologics (including molecular target drug) or radioisotopic therapy within 12 weeks before the first dose of brentuximab vedotin.
  14. Have unresolved toxicity higher than Grade 1 (National Cancer Institute [NCI CTCAE] version 4.03) attributed to any prior therapy/procedure (excluding alopecia or non- and asymptomatic laboratory abnormalities).
  15. Have received systemic at doses greater than the equivalent of 20 mg/day of prednisone within 1 week before the first dose of brentuximab vedotin.
  16. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of the safety and toxicity of the prescribed regimens.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin 1.8 mg/kg

    Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.

    Drug: Brentuximab Vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who have achieved complete remission (CR)=disappearance of all evidence of disease or partial remission (PR)=regression of greater than or equal to 50% of measurable disease and no new site by end of treatment (EOT) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment until disease progression death or end of treatment (approximately 12 months)

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs or worsens after receiving study drug.

    Time frame: First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)

  3. Number of Participants With Abnormal Clinical Laboratory Findings Reported as Adverse Events

    Clinical Laboratory tests included tests of Chemistry, Hematology and Urinalysis prespecified in the protocol. Abnormal laboratory values assessed by the investigator that lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be clinically significant changes from Baseline were recorded as Adverse Events. Neutropenia (pooled) includes preferred terms Neutropenia and Neutrophil count decreased.

    Time frame: First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)

  4. Number of Participants With Abnormal Vital Signs Reported as Adverse Events

    Vital signs included blood pressure in the sitting position, pulse rate, axillary temperature and weight. Abnormal vital sign values considered by the investigator to be clinically significant were recorded as Adverse Events.

    Time frame: First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)

Secondary outcomes

  1. Complete Remission (CR) Rate

    CR rate is defined as the percentage of participants who have achieved CR by EOT. CR is defined as disappearance of all evidence of disease per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment, and every 12 weeks during PFS follow-up period, until disease progression death or end of treatment (approximately 12 months)

  2. Duration of Response (DOR)

    DOR is defined as the time between the first documentation of objective tumor response (CR or PR) and the first subsequent documentation of objective tumor progression or death due to any cause, whichever occurs first. CR is defined as disappearance of all evidence of disease. PR is defined as regression of greater than or equal to 50% of measurable disease and no new sites.

    Time frame: Up to 3.2 years

  3. Progression Free Survival (PFS)

    PFS is defined as the time from the start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

    Time frame: Up to 3.2 years

  4. Overall Survival (OS)

    Overall survival is defined as the time from the start of treatment to the date of death.

    Time frame: Up to 3.2 years

  5. B Symptom Resolution Rate

    B Symptom Resolution Rate is defined as the percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

    Time frame: Day 1 of each cycle (each cycle was of 3 weeks) up to 30 days after last dose of study drug (approximately 12 months)

  6. Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC)

    Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  7. Cmax: Maximum Observed Serum Concentration for Total Antibody (TAb)

    Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  8. Cmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)

    Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Brentuximab Vedotin ADC

    Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  10. Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAb

    Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  11. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MMAE

    Time frame: Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  12. AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC

    Time frame: Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  13. AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAb

    Time frame: Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  14. AUC(0-∞): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MMAE

    Time frame: Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose

  15. Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing Antitherapeutic Antibodies (nATA) to Brentuximab Vedotin

    Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test to determine ATA titers. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-baseline confirmed ATA positive responses) and by nATA status. The number of participants in each baseline ATA and post-baseline ATA categories are reported.

    Time frame: Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment until disease progression, death or end of treatment (approximately 12 months)

07

Results

Posted Sep 6, 2019

Participant flow

Participants took part in the study at 7 investigative sites in China. The study was conducted from 07 November 2016 to 3 February 2020.

Participant flow — Overall Study
MilestoneBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Started309
Completed256
Not completed53
Withdrew: Lost to follow-up10
Withdrew: Death43

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who have achieved complete remission (CR)=disappearance of all evidence of disease or partial remission (PR)=regression of greater than or equal to 50% of measurable disease and no new site by end of treatment (EOT) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment until disease progression death or end of treatment (approximately 12 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Overall Response Rate (ORR)70.0 (50.60 to 85.27)66.7 (29.93 to 92.51)
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs or worsens after receiving study drug.

Time frame:
First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)309
PrimaryNumber of Participants With Abnormal Clinical Laboratory Findings Reported as Adverse Events

Clinical Laboratory tests included tests of Chemistry, Hematology and Urinalysis prespecified in the protocol. Abnormal laboratory values assessed by the investigator that lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or were considered by the investigator to be clinically significant changes from Baseline were recorded as Adverse Events. Neutropenia (pooled) includes preferred terms Neutropenia and Neutrophil count decreased.

Time frame:
First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Findings Reported as Adverse Events
ParticipantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Alanine aminotransferase increased186
Aspartate aminotransferase increased176
Gamma-glutamyltransferase increased34
Blood bilirubin increased02
Reticulocyte count decreased92
Reticulocyte count increased61
Haemoglobin decreased11
Reticulocyte percentage increased10
White blood cell count decreased43
Lymphocyte count decreased50
Lymphocyte percentage decreased20
Lymphocyte count increased01
Lymphocyte percentage increased01
Monocyte count increased01
Neutrophil count increased01
Neutrophil percentage decreased10
White blood cell count increased01
Platelet count decreased22
Blood uric acid increased21
Blood glucose increased11
Blood albumin decreased01
Protein total decreased01
Blood creatinine increased11
Blood urea decreased01
Blood urea increased01
Blood lactate dehydrogenase increased02
Blood alkaline phosphatase increased01
Blood cholesterol increased01
Blood calcium decreased01
Blood calcium increased01
Blood chloride decreased01
Blood phosphorus decreased01
Blood potassium decreased01
Blood triglycerides increased01
Glucose urine present10
Leukopenia152
Anaemia123
Hyperuricaemia42
Hypertriglyceridaemia22
Hypokalaemia32
Blood creatine phosphokinase increased11
Total bile acids increased02
Alpha hydroxybutyrate dehydrogenase increased01
Blood magnesium decreased01
High density lipoprotein decreased01
Hypercalcaemia01
Hyperglycaemia10
Hypoalbuminaemia01
Hypocalcaemia01
Hyponatraemia10
Lipoprotein (a) increased01
Low density lipoprotein increased01
Monocytosis01
Red blood cell sedimentation rate increased10
Thrombocytopenia10
Neutropenia (Pooled)195
PrimaryNumber of Participants With Abnormal Vital Signs Reported as Adverse Events

Vital signs included blood pressure in the sitting position, pulse rate, axillary temperature and weight. Abnormal vital sign values considered by the investigator to be clinically significant were recorded as Adverse Events.

Time frame:
First dose of study drug up to 30 days after last dose of study drug (approximately 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as Adverse Events
ParticipantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Weight increased42
Weight decreased12
SecondaryComplete Remission (CR) Rate

CR rate is defined as the percentage of participants who have achieved CR by EOT. CR is defined as disappearance of all evidence of disease per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment, and every 12 weeks during PFS follow-up period, until disease progression death or end of treatment (approximately 12 months)
Reported as:
Number · percentage of participants
Complete Remission (CR) Rate
percentage of participantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Complete Remission (CR) Rate20.0 (7.71 to 38.57)55.6 (21.20 to 86.30)
SecondaryDuration of Response (DOR)

DOR is defined as the time between the first documentation of objective tumor response (CR or PR) and the first subsequent documentation of objective tumor progression or death due to any cause, whichever occurs first. CR is defined as disappearance of all evidence of disease. PR is defined as regression of greater than or equal to 50% of measurable disease and no new sites.

Time frame:
Up to 3.2 years
Reported as:
Median · months
Duration of Response (DOR)
monthsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Duration of Response (DOR)12.0 (4.37 to NA)NA (1.41 to NA)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Time frame:
Up to 3.2 years
Reported as:
Median · months
Progression Free Survival (PFS)
monthsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Progression Free Survival (PFS)13.5 (6.77 to 17.81)23.2 (1.25 to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the start of treatment to the date of death.

Time frame:
Up to 3.2 years
Reported as:
Median · months
Overall Survival (OS)
monthsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Overall Survival (OS)NA (NA to NA)NA (3.19 to NA)
SecondaryB Symptom Resolution Rate

B Symptom Resolution Rate is defined as the percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

Time frame:
Day 1 of each cycle (each cycle was of 3 weeks) up to 30 days after last dose of study drug (approximately 12 months)
Reported as:
Number · percentage of participants
B Symptom Resolution Rate
percentage of participantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
B Symptom Resolution Rate50.0 (1.26 to 98.74)100.00 (15.81 to 100.00)
SecondaryCmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC)
Time frame:
Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Mean · micrograms/milliliter (ug/mL)
Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC)
micrograms/milliliter (ug/mL)Brentuximab Vedotin 1.8 mg/kg
Cycle 136.9504 ± 9.90360
Cycle 232.4341 ± 5.83197
SecondaryCmax: Maximum Observed Serum Concentration for Total Antibody (TAb)
Time frame:
Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Mean · ug/mL
Cmax: Maximum Observed Serum Concentration for Total Antibody (TAb)
ug/mLBrentuximab Vedotin 1.8 mg/kg
Cycle 138.2293 ± 7.95483
Cycle 239.9859 ± 12.43445
SecondaryCmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)
Time frame:
Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Mean · ug/mL
Cmax: Maximum Observed Plasma Concentration for Monomethyl Auristatin E (MMAE)
ug/mLBrentuximab Vedotin 1.8 mg/kg
Cycle 15.1623 ± 3.69893
Cycle 23.6218 ± 2.89331
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Brentuximab Vedotin ADC
Time frame:
Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Median · days
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Brentuximab Vedotin ADC
daysBrentuximab Vedotin 1.8 mg/kg
Cycle 10.0576 (0.031 to 0.221)
Cycle 20.0528 (0.028 to 0.214)
SecondaryTmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAb
Time frame:
Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Median · days
Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAb
daysBrentuximab Vedotin 1.8 mg/kg
Cycle 10.0653 (0.031 to 1.067)
Cycle 20.0660 (0.028 to 0.972)
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MMAE
Time frame:
Cycles (each cycle was of 3 weeks) 1 and 2: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Median · days
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MMAE
daysBrentuximab Vedotin 1.8 mg/kg
Cycle 12.0729 (1.031 to 6.991)
Cycle 22.9785 (0.178 to 6.986)
SecondaryAUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC
Time frame:
Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Mean · day*ug/mL
AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC
day*ug/mLBrentuximab Vedotin 1.8 mg/kg
AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC79.9951 ± 19.59116
SecondaryAUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAb
Time frame:
Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Mean · day*ug/mL
AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAb
day*ug/mLBrentuximab Vedotin 1.8 mg/kg
AUC(0-∞): Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAb168.6618 ± 41.62840
SecondaryAUC(0-∞): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MMAE
Time frame:
Cycle (each cycle was of 3 weeks) 1: Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose
Reported as:
Mean · day*ug/mL
AUC(0-∞): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MMAE
day*ug/mLBrentuximab Vedotin 1.8 mg/kg
AUC(0-∞): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MMAE36.8625 ± 22.79816
SecondaryNumber of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing Antitherapeutic Antibodies (nATA) to Brentuximab Vedotin

Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA development) using a laboratory test to determine ATA titers. Confirmed ATA-positive response was categorized as transient (defined as 1 or 2 post-baseline confirmed ATA-positive responses) and persistent (defined as more than 2 post-baseline confirmed ATA positive responses) and by nATA status. The number of participants in each baseline ATA and post-baseline ATA categories are reported.

Time frame:
Baseline, at Cycles (each cycle was of 3 weeks) 2, 4, 7, 10, 13, and 16 during treatment until disease progression, death or end of treatment (approximately 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing Antitherapeutic Antibodies (nATA) to Brentuximab Vedotin
ParticipantsBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Baseline ATA Negative299
Baseline ATA Negative, ATA Negative218
Baseline ATA Negative, Transiently ATA Positive71
Baseline ATA Negative, Persistently ATA Positive10
Baseline ATA Negative, nATA Negative00
Baseline ATA Negative, nATA Positive81
Baseline ATA Positive10
Baseline ATA Positive, ATA Negative0—
Baseline ATA Positive, Transiently ATA Positive0—
Baseline ATA Positive, Persistently ATA Positive1—
Baseline ATA Positive, nATA Negative0—
Baseline ATA Positive, nATA Positive1—

Adverse events

Collected over All-Cause Mortality: up to 3.2 years; Serious and Other Adverse Events: First dose of study drug up to 30 days post last dose of study drug (up to 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin 1.8 mg/kg (HL)4/30 (13.3%)1/30 (3.3%)30/30 (100%)
Brentuximab Vedotin 1.8 mg/kg (sALCL)3/9 (33.3%)1/9 (11.1%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Large intestine polypGastrointestinal disorders0/301/9
Lung infectionInfections and infestations1/300/9
Most frequent other events
Showing 10 of 99
Most frequent other events
EventBrentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)
Alanine aminotransferase increasedInvestigations18/306/9
Aspartate aminotransferase increasedInvestigations17/306/9
NeutropeniaBlood and lymphatic system disorders19/305/9
LeukopeniaBlood and lymphatic system disorders15/302/9
Gamma-glutamyltransferase increasedInvestigations3/304/9
PyrexiaGeneral disorders6/304/9
AnaemiaBlood and lymphatic system disorders12/303/9
White blood cell count decreasedInvestigations4/303/9
DiarrhoeaGastrointestinal disorders8/303/9
Reticulocyte count decreasedInvestigations9/302/9

Baseline characteristics

Safety Population included all participants who had measurable lesions at baseline and received at least 1 dose of brentuximab vedotin.

Age, Continuous
Age, Continuous(years)Brentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)Total
Mean31.9 ± 8.9141.1 ± 15.2834.0 ± 11.19
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)Total
Female13215
Male17724
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)Total
Ethnicity — Not Hispanic or Latino30939
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)Total
Race — Asian30939
Region of Enrollment
Region of Enrollment(Participants)Brentuximab Vedotin 1.8 mg/kg (HL)Brentuximab Vedotin 1.8 mg/kg (sALCL)Total
China30939
08

Study locations

7 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Sun Yat-san University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • Jiangsu Province People's Hospital
    Nanjing, Jiangsu 210029, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200010, China
09

References and documents

Publications

  • Song Y, Guo Y, Huang H, Li W, Ke X, Feng J, Xu W, Miao H, Kinley J, Song G, Dai Y, Wang H, Zhu J. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Expert Rev Hematol. 2021 Sep;14(9):867-875. doi: 10.1080/17474086.2021.1942831. Epub 2021 Aug 24. PubMed 34275403 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2018, 20 months.

Results were first posted in Sep 2019, 1 year 1 month after primary completion.

Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2016
First posted
Oct 19, 2016
StartActual
Nov 7, 2016
Primary completionActual
Aug 2, 2018
CompletionActual
Feb 3, 2020
Results first posted
Sep 6, 2019
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02939014
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 19, 2016
Start date
Nov 7, 2016
Primary completion
Aug 2, 2018
Completion
Feb 3, 2020
Results posted
Sep 6, 2019
Last update
Feb 24, 2021

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion